AZN.CA
AstraZeneca PLC
Healthcare · Drug Manufacturers - General · GB
Sep 18, 2026, 18:00 UTC
The FDA granted priority review to AstraZeneca's filing for efzimfotase alfa, a treatment for the rare bone disease hypophosphatasia (HPP).
Source:Sep 18, 2026, 10:02 UTC
AstraZeneca CEO Soriot bought ordinary shares of the company worth £7.26 million.
Source:Sep 17, 2026, 13:30 UTC
The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.
Source:Sep 17, 2026, 07:15 UTC
Bavarian Nordic A/S appointed Tarja Stenvall as President and Chief Executive Officer effective October 15, 2026, succeeding Paul Chaplin.
Sep 17, 2026, 03:26 UTC
AstraZeneca announced an investment of nearly RMB 200 million to upgrade the new drug development and supply building at its Wuxi production and supply base for process development and production of an investigational cardiovascular drug and global supply after commercialization.
Sep 15, 2026, 11:34 UTC
AstraZeneca's Japan subsidiary invited three Japanese drug-discovery and medical-device startups, including Cuorips, to its global headquarters in Cambridge, UK, for discussions on overseas expansion as part of an Osaka Prefecture-backed startup support program.
Source:Sep 15, 2026, 10:41 UTC
Zacks added Aptiv, AstraZeneca and Bank OZK to its Zacks Rank #5 (Strong Sell) list on September 15, 2026.
Source:Sep 14, 2026, 23:15 UTC
AstraZeneca (AZN) shares rose 2.25% to close at $163.78 in the latest trading session.
Source:Sep 14, 2026, 13:07 UTC
AstraZeneca disclosed that its breast cancer pill camizestrant failed in a pivotal trial testing it as a first-line therapy in advanced tumors.
Source:Sep 14, 2026, 09:15 UTC
Eris Lifesciences elevated Sanjeev Mehra to Vice President – Human Resources & Organisational Development in April 2026.
Source:Sep 14, 2026, 01:56 UTC
AstraZeneca reported that its drug Enhertu (trastuzumab deruxtecan) achieved a median progression-free survival of 14.3 months.
Sep 14, 2026, 01:48 UTC
AstraZeneca reported final safety data from the ADAURA trial showing that Tagrisso's safety profile remained consistent with no new safety concerns.
Source:Sep 14, 2026, 01:47 UTC
AstraZeneca presented the longest survival data from a global Phase III trial of Tagrisso (osimertinib) in early-stage EGFR-mutated lung cancer, showing a 47% reduction in the risk of death at eight years in patients with stage II-IIIA disease.
Sep 11, 2026, 20:17 UTC
AstraZeneca's Etcamah failed to meet the primary progression-free survival endpoint in the SERENA-4 trial.
Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:Sep 9, 2026, 00:20 UTC
On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.
Sep 8, 2026, 11:45 UTC
AstraZeneca announced that in the TITANIA study, Tozorakimab 300mg reduced the risk of moderate-to-severe exacerbations by 29% in the overall COPD patient population who are current or former smokers.
Sep 8, 2026, 06:20 UTC
China's Ministry of Commerce added 84 new key foreign-invested projects, including six landmark projects such as Fujian Benz Phase II and AstraZeneca's global strategic R&D center, with total investment of $19.46 billion.
Sep 1, 2026, 06:05 UTC
AstraZeneca completed its acquisition agreement for ZEGFROVY.
Source:Aug 28, 2026, 09:23 UTC
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.
Aug 27, 2026, 06:00 UTC
Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.
Aug 26, 2026, 03:20 UTC
Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.
Source:Aug 25, 2026, 06:52 UTC
AstraZeneca PLC priced a €2.55 billion euro bond offering across four tranches, issued by its subsidiary AstraZeneca Finance LLC with a parent guarantee, for general corporate purposes.
Aug 24, 2026, 12:30 UTC
The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.
Source:Aug 24, 2026, 07:45 UTC
The FTSE 100 index opened flat, easing 0.06% to 10,810, with AstraZeneca falling about 1% and FirstGroup dropping as much as 7% before recovering.
Source:Aug 7, 2026, 09:15 UTC
Fresnillo surged 2.74% to 2,813p, Convatec Group advanced 2.73% to 233p, BAE Systems climbed 1.68% to 2,237p, London Stock Exchange Group gained 1.53% to 8,884p, Diageo rose 1.47% to 1,758p, and AstraZeneca added 1.38% to 12,014p.
Source:
Page 1Next →